首页> 美国卫生研究院文献>Journal of Clinical Oncology >Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

【2h】

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

机译：恩沙鲁胺治疗期间单独使用阿比特龙或与恩沙鲁胺联用可治疗转移性去势抵抗性前列腺癌且前列腺特异性抗原升高

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeEnzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO ( identifier: ) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design.

机译：目的对恩杂鲁胺的耐药性可能由雄激素升高引起，可以通过与乙酸阿比特龙合用来克服。 PLATO（标识符：）使用随机，双盲，安慰剂对照的设计来询问该假设。

著录项

期刊名称 Journal of Clinical Oncology
作者
Gerhardt Attard; Michael Borre; Howard Gurney; Yohann Loriot; Corina Andresen-Daniil; Ranjith Kalleda; Trinh Pham; Mary-Ellen Taplin;
展开▼
作者单位

展开▼
年(卷),期 -1(36),25
年度 -1
页码 2639–2646
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment [J] . Attard Gerhardt, Borre Michael, Gurney Howard, Journal of Clinical Oncology . 2018,第25期

机译：单独的AbiraTerone或与苯甲丁酰胺组合在转移性阉割的前列腺癌中，在纯酰胺处理过程中具有上升前列腺特异性抗原
2. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naive, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide [J] . Miyake Hideaki, Hara Takuto, Tamura Keita, Urologic oncology . 2017,第6期

机译：在多西紫杉醇 - 幼稚园，转移性阉割的前列腺癌患者接受醋酸盐的患者的患者的患者中，抗原抗原（PSA）Nadir和PSA无进展生存之间的独立关联。
3. Clinical Outcomes and Survival Surrogacy Studies of Prostate-Specific Antigen Declines Following Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel [J] . Armstrong Andrew J., Saad Fred, Phung De, Cancer: A Journal of the American Cancer Society . 2017,第12期

机译：前列腺特异性抗原的临床结果和生存替代研究在先前用多西紫杉醇治疗的转移性阉割抗阉割前列腺癌中的男性中依齐甲酰胺下降
4. Beyond Enzalutamide and Abiraterone: What's Next in Androgen Therapy? [C] . Andrew J. Armstrong Genitourinary Cancers Symposium. . 2014

机译：除了甲甲酰胺和Abiraatorone之外：雄激素治疗中的内容是什么？
5. The Role of SOX2 in Regulating Metabolism and Enzalutamide Resistance in Prostate Cancer [D] . de Wet, Larischa . 2020

机译：SOX2在治疗前列腺癌中调节代谢和依齐甲酰胺抗性的作用
6. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer [O] . Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, 2021

机译：使用AbiraTerone和苯甲丁酰胺的第一线治疗的四周的早期前列腺特异性抗原（PSA）变化可以预测转移性阉割抗性前列腺癌的早期/致力
7. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer [O] . Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, 2021

机译：使用AbiraTerone和苯甲丁酰胺的第一线治疗的四周的早期前列腺特异性抗原（PSA）变化可以预测转移性阉割抗性前列腺癌的早期/致力

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

摘要

著录项

相似文献

相关主题

期刊订阅